These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 34349358)

  • 1. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences.
    Williams MT; Davis AK; Xin Y; Sepeda ND; Grigas PC; Sinnott S; Haeny AM
    Drugs (Abingdon Engl); 2021; 28(3):215-226. PubMed ID: 34349358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Psychedelic Use on Racial Trauma Symptoms and Ethnic Identity among Asians in North America.
    Ching THW; Davis AK; Xin Y; Williams MT
    J Psychoactive Drugs; 2023; 55(1):19-29. PubMed ID: 35012425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada.
    Haeny AM; Lopez JA; Colón Grigas PA; Crouch MC; Davis AK; Williams M
    J Subst Use Addict Treat; 2023 Jun; 149():209035. PubMed ID: 37019336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color.
    Davis AK; Xin Y; Sepeda ND; Garcia-Romeu A; Williams MT
    Chronic Stress (Thousand Oaks); 2021; 5():24705470211035607. PubMed ID: 34377878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.
    Fogg C; Michaels TI; de la Salle S; Jahn ZW; Williams MT
    Exp Clin Psychopharmacol; 2021 Oct; 29(5):539-554. PubMed ID: 34096755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model.
    Wießner I; Falchi M; Palhano-Fontes F; Feilding A; Ribeiro S; Tófoli LF
    Psychol Med; 2023 Mar; 53(4):1151-1165. PubMed ID: 34253268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision.
    Smith DT; Faber SC; Buchanan NT; Foster D; Green L
    Front Psychiatry; 2021; 12():774736. PubMed ID: 35126196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of recreational psychedelic substance use experiences classified by substance.
    Hase A; Erdmann M; Limbach V; Hasler G
    Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Past and Future of Psychedelic Science: An Introduction to This Issue.
    Doblin RE; Christiansen M; Jerome L; Burge B
    J Psychoactive Drugs; 2019; 51(2):93-97. PubMed ID: 31132970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD.
    Davis AK; Barrett FS; So S; Gukasyan N; Swift TC; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):437-446. PubMed ID: 33427007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
    Garcia-Romeu A; Davis AK; Erowid E; Erowid F; Griffiths RR; Johnson MW
    Front Psychiatry; 2019; 10():955. PubMed ID: 32038317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying.
    Sweeney MM; Nayak S; Hurwitz ES; Mitchell LN; Swift TC; Griffiths RR
    PLoS One; 2022; 17(8):e0271926. PubMed ID: 36001643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.
    Kangaslampi S; Hausen A; Rauteenmaa T
    J Psychoactive Drugs; 2020; 52(4):309-318. PubMed ID: 32511073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.